Monitor the BoxX-NoAF and LeAAPS clinical trial readouts as additional catalysts. The raised guidance supports a positive longer-term view.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 24 $35.04entry
- T+1 · 4mo ago +6.65%α +6.63% · $37.37
- T+5 · 4mo ago +14.58%α +14.21% · $40.15
- T+20 · 3mo ago +39.78%α +36.16% · $48.98
- T+60 · 29d ago +58.48%α +55.18% · $55.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AtriCure reported Q2 2026 results with a massive EPS beat of $0.18 vs $0.03 consensus (+500%), revenue of $153.6M (+12.8% YoY) and a swing to net income of $9.0M from a loss last year. The company raised full-year revenue guidance to $602M-$610M and adjusted EBITDA guidance to $85M-$89M, signaling accelerating profitability.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $153.6M, +12.8% YoY (12.4% constant currency)
- GAAP EPS $0.18 vs $0.03 consensus (500% beat)
- Net income $9.0M vs loss of $6.2M in Q2 2025
- Gross margin 77.2%, +269 bps YoY
- Adjusted EBITDA $27.3M, +78% YoY
- Full-year 2026 revenue guidance raised to $602M-$610M (from $600M-$610M)
- Full-year adjusted EBITDA guidance raised to $85M-$89M (from $80M-$82M)
- Full-year adjusted EPS guidance initiated at $0.24-$0.32
- Cash generation of $21.6M in Q2
Financial Impact
EPS beat by 500% ($0.18 vs $0.03), revenue growth 12.8% YoY, guidance raised across all metrics
Risk Factors
- Clinical trial data readouts (BoxX-NoAF, LeAAPS) are binary and could reverse sentiment
- Competition from catheter-based technologies and drugs
- Reliance on FDA approvals and reimbursement for new products
- Elevated share-based compensation ($12.3M in Q2) dilutes earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001323885-26-000032 |
| Document: atrc-20260723.htm | 0001323885-26-000032 |
| Document: 0001323885-26-000032-index-headers.html | 0001323885-26-000032 |
| Document: 0001323885-26-000032-index.html | 0001323885-26-000032 |
| Document: 0001323885-26-000032.txt | 0001323885-26-000032 |
| 8-K Data (Synthetic) | 0001323885-26-000032 |
Track record
19 reports on ATRC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $55.42 Now $55.31 −0.20% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $55.72 Now $55.31 −0.74% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $57.53 Now $55.31 −3.86% settles Feb 9
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $57.78 Now $55.31 −4.27% settles Feb 5
- Nov 6, 202610d ago Institutional Cluster Bullish 4/10 Entry $58.54 Now $55.31 −5.52% settles Feb 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $61.28 Now $55.31 −9.74% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $65.53 Now $55.31 −15.60% settles Feb 2
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $61.25 Now $55.31 −9.70% settles Jan 28
- Oct 5, 20266w ago SC 13G/A Neutral 3/10 Entry $56.37 Now $55.31 −1.88% settles Dec 30
- Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $56.22 Now $55.31 −1.62% settles Dec 9
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers